57 results about "Progestogen" patented technology

The invention belongs to the field of biological medicines, and finds and verifies that taquinimod or pharmaceutically acceptable salts thereof can be used for preparing medicines for treating endometriosis for the first time, and is particularly suitable for progestogen-resistant, recurrent or deep infiltration type endometriosis. The action mechanism of the taquinimod is as follows: the taquinimod can down-regulate the expression of S100A9 protein and reduce the infiltration of S100A9 + macrophages by inhibiting an NF-kappa B signal channel so as to further inhibit the expression of a vascular endothelial growth factor receptor 1 (VEGFR1) and a matrix metalloproteinase 2 (MMP2), finally block pathological angiogenesis and inhibit the growth of ectopic lesions. Animal experiments show that the taquinimod can significantly reduce the number and weight of nidus of a mouse model with endometriosis. The invention provides a brand-new non-hormone treatment choice with a clear action mechanism for clinical application, provides a pharmaceutical composition containing a specific dosage and a drug combination scheme, and has an important clinical value.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a medicine for treating premature ovarian insufficiency and application, the medicine comprises a modified kidney-tonifying pill, and the modified kidney-tonifying pill is prepared from radix rehmanniae preparata, Chinese yam, poria cocos, wine-prepared fructus corni, angelica sinensis, fructus lycii, salted eucommia ulmoides, salted semen cuscutae, raspberry and mulberry according to the mass ratio of 2: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1. Research finds that when a female progestational hormone sequential therapy is combined with the modified kidney-invigorating pill to treat a kidney deficiency type POI patient, clinical symptoms in multiple aspects of menstrual cycle, menstrual period, menstrual dose, soreness and weakness of waist and knees, dizziness and tinnitus, hectic fever and night sweat, sexual apathy and frequent urination at night can be remarkably improved, the serum FSH and LH levels are reduced, the E2 level is improved, and the traditional Chinese medicine composition is worthy of clinical popularization and has a wide application prospect. The theoretical basis and clinical guidance are provided for treating the kidney deficiency type POI through traditional Chinese medicine.

The invention discloses a female-breeding primary pulp composition based on a seed circulation method and a preparation method and application thereof, and relates to the technical field of functional foods.The female-breeding primary pulp composition is prepared from, by weight, 15%-25% of organic flaxseeds, 15%-25% of organic black beans, 10%-20% of figs, 10%-20% of soybeans, 5%-15% of the root of kudzu vine, 5%-15% of pumpkin seeds and 2%-8% of lycium ruthenicum. The invention also provides a preparation method of the female-nourishing protoplasm composition and application of the female-nourishing protoplasm composition in functional food for regulating the balance of female estrogen and progestational hormone. According to the female-nourishing puree composition based on the seed circulation method, various medicinal and edible raw materials are selected and scientifically compounded, a special processing technology is adopted for wall breaking and effect releasing, and the ready-to-drink puree which can be drunk fixedly every day so as to realize synchronous balance adjustment of estrogen and progesterone is prepared; the pain points of high cycle dependence, low absorption rate and inconvenience in use of the traditional method are fundamentally solved.

The invention provides a method for purifying ovarian progenitor cells and application of the ovarian progenitor cells to in-vitro generation of steroid secretion cells, and belongs to the technical field of biology. The method for purifying the ovarian progenitor cells comprises the following steps: digesting, filtering and washing an ovary, purifying through a magnetic bead or flow cytometry sorting procedure, and screening to obtain the ovarian progenitor cells, a marker used in the purification process is LY6A, LGR5 or PDGFRA (Platelet Derived Growth Factor Receptor A). Experimental results show that the PDGFRA < + > progenitor cells and the LY6A < + > progenitor cells can form androgen synthetic cells for expressing CYP11A1 and CYP17A1; and the LGR5 < + > progenitor cells can only form progestational hormone synthetic cells which express CYP11A1 but do not express CYP17A1.

The invention discloses a chemiluminescence immunoassay method and kit for detecting progestational hormone of pandas, and belongs to the technical field of biological detection. The specific process comprises the following steps: by taking goat anti-mouse IgG as a coating antibody, enabling a progestational hormone standard substance or a to-be-detected sample and horse radish peroxidase labeled progestational hormone to compete with a limited amount of progestational hormone antibodies together; after incubation and washing, a chemiluminescent substrate is added, and quantitative analysis of the progestational hormone in the panda urine or excrement is realized by detecting the intensity of a luminescent signal according to a standard curve. The invention provides a novel chemiluminescence immunoassay method, the sensitivity of the chemiluminescence immunoassay method is far higher than that of a traditional ELISA method (the lowest detection line can reach 31.25 pg / mL), the operation is simple and convenient, the detection is rapid, and the urgent demand on rapid and accurate determination of the hormone level in panda pregnancy monitoring and reproduction management can be met.

The present invention relates to an intravaginal ring (1) comprising a core (2) and a sheath (5), the core (2) containing a first ethylene-vinyl acetate copolymer (3) with a vinyl acetate content of 28-40% by weight and at least 10% by weight of an estrogen steroid (4) based on the weight of the core, and the sheath (5) containing a second ethylene-vinyl acetate copolymer (6) with a vinyl acetate content of 18-28% by weight and at least 10% by weight of a progesterone steroid (7) based on the weight of the sheath. The inventors have found that by using the intravaginal ring according to the invention it is possible to achieve an optimal independent release of the two active ingredients, i.e. estrogen steroid and progesterone steroid, without a complex assembly of components and without the use of sophisticated multi-layer extrusion techniques.

The application relates to the technical field of animal models, in particular to a modeling method and an evaluation method of an animal menstrual dysmenorrhea model and application, wherein the animal with removed ovaries is injected with estrogen, progesterone and oxytocin, the pharmacological injection of progesterone can reduce the harm and mortality rate of the animal caused by the implantation and removal of a progesterone release body in the prior art, the surgical stress of the animal is reduced, the injection time of the progesterone in the application is 7-9 days, and the animal menstrual dysmenorrhea model is obtained after the progesterone is withdrawn for 16 hours; after evaluation by the evaluation method, compared with the non-menstrual process of the dysmenorrhea model in the prior art, the animal menstrual dysmenorrhea model can better simulate the pathophysiological process of human dysmenorrhea, promote the development of clinical treatment, and effectively help patients to relieve pain.

The invention belongs to the technical field of medicine dosage forms, and particularly relates to a conjugated estrogen-progestational hormone double-layer tablet and a preparation method thereof. The preparation method comprises the following steps: performing powder mixing on conjugated estrogen and a first medicine auxiliary material to obtain conjugated estrogen powder; carrying out wet granulation on progestational hormone and a second medicine auxiliary material to obtain progestational hormone granules; and tabletting the conjugated estrogen powder and the progestational hormone particles by using a double-layer tablet press to obtain the conjugated estrogen-progestational hormone double-layer tablet. The conjugated estrogen-progestational hormone double-layer tablet prepared by the invention can simultaneously meet the slow release of conjugated estrogen and the quick release of progestational hormone, so that the medicine taking frequency is reduced, and the compliance of a patient is improved; and meanwhile, the stability of a drug bound with estrogen and the bioavailability of progestational hormone are improved.

The invention relates to the field of blood-enriching oral liquid, in particular to Zhenqi blood-enriching oral liquid. Sheep placentas, pearls, red ginseng, Chinese wolfberry fruits, astragalus membranaceus, radix angelicae, coix seeds, fresh ginger, Chinese dates, black beans, angelica sinensis, radix puerariae and Chinese herbaceous peony are used as functional component raw materials. The sheep placenta is hydrolyzed by pancreatin to obtain hydrolysate rich in protein, polypeptide, amino acid, collagen, female progestational hormone and the like, and the palatability of the oral liquid is improved through deodorization and decoloration treatment of activated carbon. Neutral protease is firstly added into pearls for enzymolysis, then hydrochloric acid is added for hydrolysis, and protein is converted into a water-soluble component with smaller molecular weight. The pearl hydrolysate is good in water solubility, high in absorptivity and rich in active substances. Soybean isoflavone contained in the black beans is similar to estrogen secreted by a human body in structure. Paeonia lactiflora has the functions of dredging channels and promoting blood circulation. And the other nine blood-enriching traditional Chinese medicines are mutually coordinated to achieve the purposes of nourishing yin and blood, enriching blood and soothing nerves. Qi and blood are effectively regulated, and hypomenorrhea and thin menstruation are treated.

The present invention relates to an intravaginal ring (1) a core (2) comprising a first ethylene-vinyl acetate copolymer (3) having a vinyl acetate content from 28 to 40 wt %, and at least 10 wt % of an estrogenic steroid (4) based on the weight of the core, and a sheath (5) comprising a second ethylenevinyl acetate copolymer (6) having a vinyl acetate content from 18 to 28 wt %, and at least 10 wt % of a progestational steroid (7) based on the weight of the sheath. Using the intravaginal ring according to the present the inventors have found that it is possible to attain independent and optimal release of the two active ingredients: an estrogenic steroid and a progestational steroid, without the need for complex assembly of parts and without the need to use sophisticated multi-layer extrusion technology.

The present invention relates to injectable microspheres and formulations comprising the microspheres for controlled release of progestogen hormones.

Provided herein are methods of determining tumoral sensitivity to hormonal (endocrine) therapy based upon an index of estrogen receptor (ER)- and progesterone receptor (PR)-related genes, referred to as the sensitivity to endocrine therapy index (SETER / PR index), and may have additional consideration for the proportion of ER gene (ESR1) RNA transcripts that contain a mutation relative to the value of the SETER / PR index. Further provided are methods of treating breast cancer patients determined to be sensitive to an endocrine therapy by the SETER / PR index.

The invention relates to a method for simultaneously detecting various steroid hormones in serum, which comprises the following steps: extracting hormones in serum by a liquid-liquid extraction method; a derivatization reagent is added into the extracted hormone, an oximation reaction is carried out, and the derivatization reagent comprises quaternary ammonium oxygen amine; the hormone after oximation reaction is injected into a two-dimensional liquid chromatography-tandem mass spectrometry system for detection, the hormone is enriched on a one-dimensional chromatographic column, and then the enriched hormone is subjected to back flushing and transferred to a two-dimensional chromatographic column for analysis. According to the method, the backwashing transfer two-dimensional liquid chromatography-tandem mass spectrometry and the derivatization reaction are combined, various steroid hormones including progestational hormone and androgen can be detected at the same time, and the method has the advantage of being high in detection sensitivity.

An improved long-acting injectable depot suspension formulation of LB displaying progestational effects which overcomes the aggregation and physical instability of LB injectable depot products, and also provides a longer duration of action of at least 4 months. Potential uses of this formulation include but are not limited to contraception and treatment or prevention of progestin / progesterone-sensitive reproductive tract dysfunctions and disorders.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to sublingual lozenges of progesterone and analogues thereof as well as a preparation method and application of the sublingual lozenges. Specifically, a novel sublingual administration dosage form which is more suitable for being absorbed by a human body is designed according to physicochemical properties of progesterone and analogues thereof. The sublingual lozenge is composed of a main drug, a filler, a disintegrating agent, a mucous membrane promoter, a flavoring agent, a lubricant and the like. The sublingual lozenge is quickly disintegrated under the action of saliva, is quickly absorbed through tongue mucosa, takes effect quickly, avoids the first-pass effect, improves the bioavailability, and is suitable for various clinical scenes needing quick and efficient progestational hormone support.

The invention provides a chemical synthesis method of 20 alpha-hydroxyprogesterone, and belongs to the technical field of organic synthesis. The invention provides a simple and efficient synthesis path, and high-purity 20 alpha-hydroxyprogesterone can be obtained with good yield and extremely high stereoselectivity and specificity. The method is easy and convenient to operate and good in reproducibility, and effectively overcomes the defects that a product is an isomer mixture, separation and purification are difficult, and the target product yield is low in a traditional method. The successful implementation of the invention provides a stable and reliable material source for obtaining sufficient high-purity 20 alpha-hydroxyprogesterone, powerfully supports the subsequent activity research, dosage form development and new drug creation of the compound, and has important significance in the field of health drugs for women, health protection and health protection. The compound shows important application value and potential in the field of research and development of novel progesterone drugs.

The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.

An improved long-acting injectable depot suspension formulation of LB displaying progestational effects which overcomes the aggregation and physical instability of LB injectable depot products, and also provides a longer duration of action of at least 4 months. Potential uses of this formulation include but are not limited to contraception and treatment or prevention of progestin / progesterone-sensitive reproductive tract dysfunctions and disorders.

The invention belongs to the technical field of medicines, and particularly relates to application of a licorice extract in preparation of a medicine for treating premature ovarian failure. On the basis of network pharmacology prediction and animal experiment verification, through experimental exploration, it is clear that diammonium glycyrrhizinate can treat premature ovarian failure by improving ovarian tissue energy metabolism, reducing the oxidative stress level and inhibiting ovarian cell apoptosis, and also can treat premature ovarian failure by improving the ovarian growth and development microenvironment. According to the present invention, the growth and development rate of ovarian granular cells and membrane cells is improved, the sufficient quantity of granular cells and membrane cells are ensured to secrete female progestational hormone, the damaged ovarian tissue is further protected, the new strategy and hope are provided for the treatment of premature ovarian failure, and the pharmaceutical composition is expected to become the safe and effective treatment drug.

The present application belongs to the technical field of natural polymer materials, and particularly relates to a purified polysaccharide of Rhizoma Polygonati, a preparation method thereof and application of the purified polysaccharide in preparation of a medicine for relieving mammary gland hyperplasia. The purified polysaccharide of Rhizoma Polygonati comprises xylose, mannose, glucose and galactose, and the molar ratio of the xylose, mannose, glucose and galactose is 6.45:30.26:7.43:55.87. The molecular weight distribution of the purified polysaccharide of Rhizoma Polygonati is within 2000-30000 Da, and the molecular weight is concentrated at 22877 Da. The purified polysaccharide of Rhizoma Polygonati can reduce the toxic damage of estrogen and progesterone imbalance to HC11 mammary epithelial cells, and a low concentration of the purified polysaccharide of Rhizoma Polygonati can produce a protective effect on the cells. The purified polysaccharide of Rhizoma Polygonati is verified to have a significant inhibitory effect on mammary gland hyperplasia of mice through a mammary gland hyperplasia model intervention experiment, and therefore can be used for developing a medicine for treating mammary gland hyperplasia.

The present invention relates to injectable microspheres and formulations comprising the microspheres for controlled release of progestogen hormones. The present invention also relates to a method of preparing the microspheres that control the release of the progestogen hormone and methods of using the microspheres that control the release of the progestogen hormone to treat conditions such as pregnancy and fertility in women as well as gynecological disorders such as secondary amenorrhea, endometriosis, abnormal uterine bleeding due to hormonal imbalance, and acne.

The subject of the application is a dietary supplement containing 2.5 - 7 wt.% indole-3-carbinol, 2 - 6 wt.% epigallocatechin gallate, 30 - 70 wt.% myo-inositol, 6 - 12.5 wt.% N-acetylcysteine, 2.5 - 7 wt.% quercetin, 5 - 8.5 wt.% Omega-3 acid, 5 - 8.5 wt.% alphalipoic acid, 2 - 6 wt.% vitamin C, 1 - 5 wt.% resveratrol, 0.01 - 0.2 wt.% vitamin D3, 0.5 - 3.5 wt.% vitamin E, 0.2 - 15 wt.% alpha-lactalbumin, 0.04 - 20 wt.% curcumin, 0.2 – 15% w / w D-chiroinositol, 0.2- 24% w / w inulin, a probiotic consisting of a mixture of strains of the Lactobacillus, Bifidobacterium and Saccharomyces genera for patients with reproductive system diseases supporting the reduction of estrogen levels and estrogen and progesterone receptors.

Aspects of the disclosure relate to a composition and methods for treating breast cancer using a cannabinoid-based nanoplatform. The composition comprises phytocannabinoids, including THC, CBD, CBG, and CBC, incorporated into nanoparticles for enhanced bioavailability and controlled release. The method involves administering the composition to patients with breast cancer, particularly stages I and II, to inhibit VEGF pathways and induce apoptosis. The treatment targets estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), HER2-positive, and triple-negative breast cancers. Aspects of the disclosure further provide the production of the composition using nano emulsification techniques to create nanoparticles smaller than 200 nm. This composition offers a novel, targeted approach to reducing tumor growth and metastasis in breast cancer patients.

Provided include methods, compositions and kits for treating hormone receptor positive (HR+) breast cancer, e.g., estrogen receptor positive (ER+) and progesterone receptor positive (PR+) breast cancer, in a subject. The method can comprise administrating a PI3K inhibitor and a cell cycle inhibitor, such as a PLK1 inhibitor, to the subject in a manner sufficient to inhibit or reduce progression of the cancer.

The invention relates to a traditional Chinese medicine effective component screening method based on a chemical fingerprint spectrum and multi-omics combined analysis. The method comprises the following steps: preparing a semen cuscutae-fructus lycii medicine pair extract and establishing a UPLC-Q-TOF-MS / MS chemical fingerprint spectrum; detecting the levels of estradiol, luteinizing hormone, anti-mullerian hormone and follicle-stimulating hormone in the premature ovarian insufficiency animal model; screening characteristic components related to the drug effect through multivariate statistical analysis; performing transcriptome sequencing on the ovarian tissue, and combining GO / KEGG analysis to determine a key pathway; integrating database prediction targets and differential genes, screening hub genes and constructing a protein interaction network; and finally verifying the binding activity of the candidate component and the core target protein through molecular docking and molecular dynamics experiments. According to the invention, systematic screening and action mechanism analysis of drug effect related components are realized, and a new technical approach is provided for mass marker determination and estrogen simulating action research of the dodder-wolfberry drug pair.

The present invention discloses a system for dynamically detecting the fertile and infertile periods of women. By recording menstrual information, the system automatically marks and generates the number of days in the menstrual cycle, records and collects the basal body temperature data of the user, uses a temperature sensor to accurately measure the user's basal body temperature, and the measurement results are directly automatically entered by the system to construct a comparison database of the menstrual period and the basal body temperature. Subsequently, based on the fact that after a woman ovulates, the progesterone secreted by the ovary can cause the basal body temperature to rise. The most important thing is to determine which day is the first high-temperature period after ovulation. The method is that the system compares the basal body temperature data recorded on the current day with the highest value of the most recent 6 recorded body temperature data in the front to determine whether the body temperature today has an upward trend. Based on this theory, the detection of the infertile period after a woman ovulates is realized. The advantages of the present invention are that based on the accurate comparison of basal body temperature data, and the detection method is realized based on a temperature sensor, with fewer interference parameters, making the detection accuracy higher.

The present invention relates to a combined oral contraceptive with a reduced risk of side effects (including a reduced risk of QT interval prolongation, a reduced risk of testosterone reduction, and a reduced risk of elevated C-reactive protein levels) when compared to other combined oral contraceptives. The estetrol / drospirenone combined oral contraceptive described herein exhibits favorable pharmacokinetics of the progestogen component. The use of a specific estrogen component in a combined oral contraceptive brings multiple beneficial effects compared to currently available combined oral contraceptives.

A system, a sensor and a control unit for determining validity of a result of a lateral flow test, whereby a lateral flow stick that has a sample pad, a conjugate pad having antibody treated gold particles, and a porous membrane for receiving a capillary flow of a milk sample. The porous membrane has a test line treated with a progesterone reference which binds antibody treated gold particles of the milk sample and thereby brings the test line to change colour tint when exposed for milk comprising a progesterone level lower than a threshold limit, and a control line treated with an antibody reference which binds antibody, and thereby brings the control line to change colour tint when exposed for milk comprising antibody treated gold particles.

Provided herein are methods of determining sensitivity to dose intense chemotherapy regimens based upon an index of estrogen receptor (ER)- and progesterone receptor (PR)-related genes, referred to as the sensitivity to endocrine therapy index (SETER / PR index). Further provided are methods of treating cancer patients determined to be sensitive to dose intense chemotherapy therapy by the SETER / PR index. Also provided herein are methods for determining prognosis based on the SET2,3 index.